RT Journal Article
SR Electronic
T1 Serum anion gap is associated with all-cause mortality among critically ill patients with congestive heart failure
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.24.20161463
DO 10.1101/2020.07.24.20161463
A1 Yiyang Tang
A1 Wenchao Lin
A1 Lihuang Zha
A1 Xiaofang Zeng
A1 Zhenghui Liu
A1 Zaixin Yu
YR 2020
UL http://medrxiv.org/content/early/2020/07/24/2020.07.24.20161463.abstract
AB Background Congestive heart failure (CHF) is a complex clinical syndrome, with high morbidity and mortality. Serum anion gap (SAG) has been known to be associated with the severity of various cardiovascular diseases. However, the role of SAG indicators in CHF is unclear.Methods and results A retrospective analysis of data from MIMIC-III v1.4 was conducted in critically ill patients with CHF. Clinical information of each patient, including demographic data, comorbidities, vital signs, scores, and laboratory indicators, were successfully obtained. Cox proportional hazards models were performed to determine the relationship between SAG and mortality in CHF patient, the consistency of which was further verified by subgroup analysis.Results A total of 7426 subjects met the inclusion criteria. In multivariate analysis, after adjusting for age, gender, ethnicity, and other potential confounders, higher SAG was significantly related to an increase in 30-day and 90-day all-cause mortality of critically ill patients with CHF compared with lower SAG (tertile3 vs tertile1: adjusted HR, 95% CI: 1.74, 1.46–2.08; 1.53, 1.32–1.77). In subgroup analysis, the association between SAG and all-cause mortality present similarities in most strata.Conclusion SAG at admission can be a promising predictor of all-cause mortality in critically ill patients with CHF.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis study is a retrospective study based on the MIMIC-III v1.4, a freely accessible critical care database.This registration is not mandatory for retrospective studies.Funding StatementOur study was supported by the National Natural Science Foundation of China (81873416) and the National Science and Technology Major Project (2017ZX0930401405).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The MIMIC-III database has received ethical approval from the institutional review boards (IRBs) at Beth Israel Deaconess Medical Center and Massachusetts Institute of Technology. Because the database does not contain protected health information, a waiver of the requirement for informed consent was included in the IRB approval.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesPublicly available datasets were analyzed in this study. This data can be extracted from Monitoring in Intensive Care Database III version 1.4 (MIMIC-III v.1.4) after passing on the required courses and obtaining the authorization. https://mimic.physionet.org/